Over 60 manuscripts since 2015 from PARTNER I and PARTNER II, including landmark papers in The New England Journal of Medicine, JAMA, and The Lancet.
The JETSTREAM Calcium study showed increased lumen dimensions by IVUS in femoral-popliteal lesions by removing superficial calcium with the Jetstream Atherectomy System without major complications.
The CRF Publications Office has published over 300 papers since 2007 from ACUITY, HORIZONS-AMI, INFUSE-AMI, PROSPECT, and other studies.
HORIZONS-AMI investigators found that sustained ventricular tachycardia/fibrillation after primary PCI was not significantly associated with 3-year mortality or major adverse clinical events.
NIRS imaging used to detect lipid core containing plaque in the CANARY, YELLOW, and COLOR studies was analyzed at the CRF IVI Core Lab.
PARTNER investigators found that the relationship between moderate/severe pulmonary hypertension and increased mortality after TAVR is altered by sex, and clinical factors appear to be more influential in stratifying risk than hemodynamic indices.
In the HORIZONS-AMI trial, the development of new-onset congestive heart failure within 2 years after contemporary PCI, although infrequent, was associated with significantly increased rates of mortality and major adverse ischemic events.
Get in touch.
For over 20 years, the CTC has contributed to key advances in the treatment of cardiovascular disease and played an essential role in bringing innovative new technologies, pharmacologic therapies, and treatment paradigms to patients.
To find out more about CRF Clinical Trials Center and how we can best serve your needs.